THANK YOU FOR JOINING US AT THE 37TH ANNUAL
LORNE CANCER CONFERENCE

On behalf of the Organising Committee, we invited you to support the 37th Lorne Cancer Conference, which was held from Thursday 13th to Saturday 15th of February 2025.

If you were a past participant, you would have been aware of the history, ambience, and vibrancy of this meeting. Immediately following the Lorne Proteins meeting, Lorne Cancer featured strong international and national scientific content and attracted a capacity audience of up to 500 delegates. These delegates represented many of the major hospitals, universities, research institutes, and biotechnology companies within Australia.

Notably, along with the usual representation of biomedical research leaders from across Australia, an increasing proportion of these delegates included clinician scientists and clinical opinion leaders to facilitate translational and clinical aspects of the meeting. Thus, there were excellent opportunities for pharmaceutical companies to interact directly with key decision-makers and influencers, to strengthen their positions in the industry, to showcase their products or services face-to-face, and to develop new partnerships and networks with a motivated and targeted audience.

One of the hallmarks of the meeting over many years had been the friendly and frequent interactions between delegates and the companies supplying equipment, reagents, and pharmaceuticals. In 2024, we had envisaged a full complement of international speakers and in-person delegates; therefore, opportunities for the meeting’s sponsors to advertise and interact were facilitated by numerous planned sessions.

We appreciated working with you to maximise your experience and benefits from Lorne Cancer 2025, which was again managed by ASN, and we were delighted to see you in Lorne!

Prof Jane Visvader and Prof Wayne Tilley
Co-convenors, Lorne Cancer Conference 2025